Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Serial studies have demonstrated that induction therapy with FLAM [flavopiridol (alvocidib) 50 mg/m(2) days 1–3, cytarabine 667 mg/m(2)/day continuous infusion days 6–8, and mitoxantrone (FLAM) 40 mg/m(2) day 9] yields complete remission rates of nearly 70% in newly diagnosed poor-risk acute myeloid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica
Hauptverfasser: Zeidner, Joshua F., Foster, Matthew C., Blackford, Amanda L., Litzow, Mark R., Morris, Lawrence E., Strickland, Stephen A., Lancet, Jeffrey E., Bose, Prithviraj, Levy, M. Yair, Tibes, Raoul, Gojo, Ivana, Gocke, Christopher D., Rosner, Gary L., Little, Richard F., Wright, John J., Doyle, L. Austin, Smith, B. Douglas, Karp, Judith E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Ferrata Storti Foundation 2015
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800702/
https://ncbi.nlm.nih.gov/pubmed/26022709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.125849
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge